Edited Transcript of CVSI earnings conference call or presentation 8-May-19 8:30pm GMT

Thomson Reuters StreetEvents - finance.yahoo.com Posted 2 years ago

Q1 2019 CV Sciences Inc Earnings Call

LAS VEGAS May 10, 2019 (Thomson StreetEvents) -- Edited Transcript of CV Sciences Inc earnings conference call or presentation Wednesday, May 8, 2019 at 8:30:00pm GMT

TEXT version of Transcript

================================================================================

Corporate Participants

================================================================================

* Joseph Dowling

CV Sciences, Inc. - CEO

* Joerg Grasser

CV Sciences, Inc. - CFO

================================================================================

Conference Call Participants

================================================================================

* Mike Grondahl

Northland Capital Markets - Analyst

* Scott Fortune

ROTH Capital Partners - Analyst

================================================================================

Presentation

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

Greetings and welcome to the CV Sciences first-quarter 2019 conference call. (Operator Instructions) and this conference is being recorded. With us today with prepared remarks is CV Sciences' Chief Executive Officer, Joseph Dowling, and Joerg Grasser, Chief Financial Officer. Following the formal presentation management will take questions from the analyst community.

Before I turn the call over to management I would like to remind you that during this call management's prepared remarks may contain forward-looking statements which are subject to risks and uncertainties and management may make additional forward-looking statements during the Q&A session. These forward-looking statements are subject to risks and uncertainties and actual results may differ materially.

When used in this call the words anticipate, could, enable, estimate, intend, expect, believe, potential, will, should, project and similar expressions as they relate to CV Sciences are such forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those anticipated by CV Sciences at this time.

In addition other risks are more fully described in CV Sciences' public filings with the US Securities and Exchange Commission, which can be reviewed at www.SEC.gov.

Finally, please note on this call today management will refer to non-GAAP financial measures which in CV Sciences exclude certain expenses from its GAAP financial results. Please refer to CV Sciences' press release and the 10-Q from earlier today for a full reconciliation of non-GAAP performance measures to the most comparable GAAP financial measures.

This afternoon, May 8, the Company filed its 10-Q with the SEC and issued a press release announcing its financial results. Participants on this call who may not have already done so may wish to look at these documents as the Company provides a summary of the results on this call.

I'd now like to turn the conference over to CV Sciences' Chief Executive Officer, Mr. Joseph Dowling, who will provide an overview of the Company's business activities and developments and then run through the financials for the first quarter of 2019. Following these remarks we will open up for questions and answers at the end of the conference. Thank you, you may begin.

--------------------------------------------------------------------------------

Joseph Dowling, CV Sciences, Inc. - CEO [2]

--------------------------------------------------------------------------------

Thank you very much. Good afternoon, everyone, and thank you for joining our call today. It is my pleasure to have Joerg Grasser, our recently appointed Chief Financial Officer, with me today.

Joerg joined the Company in December 2018 as our Chief Accounting Officer coming from a background of more than 20 years of experience and an extensive background in accounting, finance, financial reporting and operations.

Prior to joining CV Sciences he most recently served as Controller of Ballast Point, Brewing, a subsidiary of Constellation Brands. During the last few months he's been an invaluable member of our team and was the clear choice to fill this role.

Story continues

With that let me take a minute to run through highlights of the quarter and then I will let Joerg run through our financials. I will finish off our prepared remarks with comments on our business developments before opening the line for Q&A.

The first quarter was a milestone for CV Sciences as we shipped our first order to the national drug retailer CVS, marking the beginning of what we believe will be broad expansion of CBD products across national food, drug and mass merchandiser accounts. We initially did not disclose the name of this large new account under agreement with the customer, but have since been given permission to discuss publicly.

Currently our PlusCBD balm is available in stores across about a half a dozen states. In total we added over 1,000 new retail doors during the first quarter alone and generated 85% revenue growth to a record $14.9 million with good gross margin performance and positive cash flow. Our PlusCBD brand continues to be the number one selling hemp-based CBD product line in the natural products retail channel according to the data aggregator spend SPINS.

In addition, we are currently conducting pilot programs with several other large FDM retailers and look forward to providing an update on these partnerships at an appropriate time.

The first-quarter growth, both year-over-year and sequentially, was achieved despite the anticipated short-term disruption in three or four states that we discussed last quarter. On our 2018 earnings call, we communicated on pressure placed on retailers from state-level public health departments who have issued cautionary comments or policy statements on hemp-based CBD accessibility. These state-by-state differences are the result of being in a period of state-level oversight with differing CBD regulation as the industry awaits the regulatory process to play out at the FDA.

California has been a particularly difficult state due to aggressive action by the Department of Public health. However, there is some very positive state legislative efforts, including in California, that will be extremely beneficial and provide clarity to the hemp industry.

An example of this is assembly Bill 228 in California. This legislation has passed through two legislative committees with unanimous support and is widely expected to pass as early as July 1. The Bill would allow the inclusion of industrial hemp or cannabinoid extracts and derivatives in food, beverages or cosmetics.

California is an extremely important market with a population of 40 million people and this legislation is timely and critical as we expand our industry and this product category. We know that Governor Newsom is a true forward thinker who championed cannabis legislation in California and we look forward to working with his administration, just as we have done in other states, to allow the hemp industry and hemp-based CBD products to continue to prosper.

Now let me turn it over to Joerg to run through our financials.

--------------------------------------------------------------------------------

Joerg Grasser, CV Sciences, Inc. - CFO [3]

--------------------------------------------------------------------------------

Thank you, Joe, and good afternoon, everyone. I'm honored to speak with you today. I'm very excited about my new role and look forward to starting a dialogue with all of you in the future.

During the first quarter we generated 85% revenue growth to $14.9 million compared to $8.1 million in Q1 2018. This growth was driven by rising consumer interest in and demand for hemp-based CBD, new product launches and the further expansion of our retail distribution footprint.

We entered the first quarter with PlusCBD Oil branded product sold in 3,308 retail stores nationwide, a 45% increase from the end of the fourth quarter of 2018. Rising consumer demand and growth across each of our distribution channels contributed to our strong revenue growth during the first quarter. However, please note that initial shipments to our largest new account came near the end of the quarter and did not contribute significantly to our first-quarter net revenue.

Our strong year-over-year revenue growth translated into a 90% increase in gross profit and a 190 basis point increase in gross margin to 70.8% of net revenue in Q1 2019 compared to 68.9% in Q1 2018.

In the first quarter we generated adjusted EBITDA of $1.7 million compared to $1.8 million in the first quarter of 2018. The modest decline reflects investments we have made in additional management resources and business systems to support our continued growth.

On a GAAP basis, for the first quarter of 2019 we reported a net loss of $9.4 million or $0.10 per share compared to net income of $0.6 million or $0.01 per fully diluted share in the first quarter of 2018. The net loss in the current period included $7.9 million of non-cash stock compensation expense and $0.9 million of payroll expense, both associated with the retirement of our founder, as well as $2.1 million of additional non-cash stock compensation expense.

Adjusted net income for the first quarter of 2019, excluded (sic - excluding) these expenses I mentioned, was $1.5 million or $0.01 per fully diluted share. This compares to adjusted net income in the prior period of $1.7 million or $0.02 per fully diluted share.

Our operations and organic growth have continued to strengthen our balance sheet. As we ended the first quarter of 2019 with $13.6 million of cash. We generated $0.8 million of cash from operations during the first quarter of 2019 and increased our cash balance by $1 million. Inventory at the end of the first quarter amounted to $8.7 million, slightly up from $8.6 million at year-end. Inventories are continuing to be scaled up to meet market demand.

Now I will turn the call back over to Joe to discuss business development.

--------------------------------------------------------------------------------

Joseph Dowling, CV Sciences, Inc. - CEO [4]

--------------------------------------------------------------------------------

Thank you, Joerg. Our business development activities remain robust. As we noted last quarter, the passage of the 2018 Farm Bill has significantly expanded retailer interest across the channels of distribution which materialized into new distribution in the first quarter. We are currently in conversations with multiple additional national retailers and in some cases in pilot programs with retailers. We expect to see addition to distribution wins over the coming months.

Our history in the category, our production capabilities, product quality and science are resonating with retailers. We are also developing new products to support our retail growth including additional topicals as we have seen the greatest near-term retailer acceptance of topical products.

Our balm is already our second best selling SKU and we see opportunities to expand this area of our portfolio. For example, we are currently testing a roll-on product and it has received favorable response from retailers.

To support for growth we are making progress on our 2019 initiatives, including the implementation and deployment of efficiency and automation resources including sales force, to enhance all of our sales and marketing initiatives and support our e-commerce expansion. In addition, we are also well into the planning phase for an expansion of our manufacturing and fulfillment capabilities to support our growth needs beyond 2019.

With the passage of the 2018 Farm Bill we have also worked diligently to secure domestic sources is in support of planned growth in 2019 and beyond. Our goal is to position the Company to be the industry leader and these investments are in support of opening new larger retail markets.

Let me also note that we are proud and committed to providing our PlusCBD products to researchers for use in clinical studies. One recent small study published in the Journal of Alternative and Complementary Medicine in April, examine the clinical benefit of CBD for patients with post-traumatic stress disorder. With the evolving regulatory environment for hemp-based CBD we believe additional research is an invaluable component of long-term market growth.

Now a brief update on our drug development operating segment. Our preclinical program for our lead drug candidate, CVSI-007 combining cannabidiol and nicotine in treatment of smokeless tobacco use and addiction, continues to make progress. We believe strongly in the potential of our drug development program and the multi-billion-dollar opportunity of addressing the huge unmet need of treating smokeless tobacco use and addiction.

We anticipate that we will be presenting in Q3 and Q4 of 2019 both initial results from our preclinical studies and discussion on our clinical strategy. We will keep you posted on the timing of those announcements.

  • 1
  • 2